Overview of Polypharmacy and Drug Interactions in Chronic Kidney Disease Patients at Siloam Hospitals Lippo Village
Abstract
Patients diagnosed with CKD in Indonesia have increased from 2% in 2013 to 3.8% in 2018. Polypharmacy is commonly found in CKD patients, especially in CKD patients with comorbidities. CKD with comorbidities will make the treatment more complex and expensive. This study was conducted to assess the relationship between polypharmacy and drug interactions in CKD patients. Data analysis was carried out descriptively on CKD patients at "X" Hospital in the period October to December 2022 and data were displayed in the form of tables and graphs. The results showed that the majority of patients with chronic kidney disease (CKD) were aged 46-65 years with 42 patients (50.0%). Chronic kidney disease (CKD) patients who get prescriptions for more than 5 drugs are 80 (95.2%) patients. Comorbidities that often occur in chronic kidney disease (CKD) patients are hypertension with 62 (19.62%) patients, diabetes mellitus with 29 (9.18%) patients, and coronary heart disease with 27 (8.54%) patients. From 84 patients, there were 626 potential drug interactions including 152 (24.28%) drug interactions with minor severity, 434 (69.33%) drug interactions with moderate severity, and 40 (6.39%) drug interactions with major severity. CKD patients who have one or more comorbidities will increase the risk of polypharmacy and an increased risk of drug interactions.
References
Riskesdas. (2018). Laporan
Riskesdas 2018 Nasional.pdf. In
Lembaga Penerbit Balitbangkes (p.
.
Agustin, O. A., & Fitrianingsih, F. (2021).
Kajian Interaksi Obat Berdasarkan
Kategori Signifikansi Klinis Terhadap
Pola Peresepan Pasien Rawat Jalan Di
Apotek X Jambi. Electronic Journal
Scientific of Environmental Health
And Disease, 1(1), 1–10.
https://doi.org/10.22437/esehad.v1i1.
Cascorbi, I. (2012).
Arzneimittelinteraktionen: Prinzipien,
Beispiele und klinische Folgen.
Deutsches Arzteblatt International,
(33–34), 546–556.
https://doi.org/10.3238/arztebl.2012.0
Cepeda, O. A., & Morley, J. E. (2012).
Polypharmacy. Pathy’s Principles
and Practice of Geriatric Medicine:
Fifth Edition, 1(1), 145–152.
https://doi.org/10.1002/97811199529
ch13
Kovesdy, C. P. (2022). Epidemiology of
chronic kidney disease: an update
Kidney International
Supplements, 12(1), 7–11.
https://doi.org/10.1016/j.kisu.2021.11.
MacRae, C., Mercer, S. W., Guthrie, B., &
Henderson, D. (2021). Comorbidity in
chronic kidney disease: A large crosssectional
study of prevalence in
Scottish primary care. British Journal
of General Practice, 71(704), E243–
E249.
https://doi.org/10.3399/bjgp20X7141
Okunade, K. (2018). Profiles of Sugar
Fermenting Bacteria of the Oral
Cavity among Children with Dental
Caries Attending Stomatology
Services at Ruhengeri Referral
Hospital in Musanze District,
Northern Rwanda. January, 19–26.
https://doi.org/10.4103/npmj.npmj
Shahzadi, A., Sonmez, I., Kose, C., Oktan,
B., Alagoz, S., Sonmez, H., Hussain,
A., & Akkan, A. G. (2022). The
Prevalence of Potential Drug-Drug
Interactions in CKD-A Retrospective
Observational Study of Cerrahpasa
Nephrology Unit. Medicina
(Lithuania), 58(2), 1–10.
https://doi.org/10.3390/medicina5802
Sleem A., Masood I., K. T. M. (2017).
Clinical relevancy and determinants
of potential drug – drug interactions
in chronic kidney disease patients :
results from a retrospective analysis.
–77.
.png)
